Pressmeddelande -
Pfizer to purchase sanofi-aventis rights to EXUBERAâ in application of change of control clauses
Sanofi-aventis announced today the signature of an agreement to transfer its rights to Exuberaâ,
an inhaled human insulin, to Pfizer. Aventis and Pfizer formed an Alliance in 1998 to jointly
develop, manufacture and market an inhaled insulin, Exuberaâ.
The contracts governing this
Alliance contained change of control clauses which Pfizer chose to exercise following the
acquisition of Aventis by Sanofi-Synthelabo.
Under the terms of the agreement signed today, sanofi-aventis will sell its share of the worldwide
rights for the development, production and commercialization of Exuberaâand its share of the
Diabel joint-venture, a company based in Frankfurt, Germany, and owner of the production
facility which manufactures the bulk insulin used in the production of Exuberaâ.
For the assets and rights transferred, sanofi-aventis will receive a payment of US$ 1.3 billion net
of German local taxes. The completion of the transaction is subject to certain closing conditions,
notably approval from the German anti- trust authorities, and is expected to occur in the first
quarter of 2006.
About sanofi- aventis
Sanofi-aventis is the worlds third- largest pharmaceutical company, ranking number one in
Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading
positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology,
metabolic diseases, central nervous system, internal medicine, and vaccines. Sanofi-aventis is
listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical
facts. These statements include financial projections and estimates and their underlying
assumptions, statements regarding plans, objectives and expectations with respect to future
operations, products and services, and statements regarding future performance. Forwardlooking
statements are generally identified by the words expect, anticipates, believes,
intends, estimates, plans and similar expressions. Although sanofi-aventis management
believes that the expectations reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and generally beyond the control
of sanofi-aventis, that could cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include those discussed or identified in the public filings with the
SEC and the AMF made by sanofi-aventis, including those listed under Risk Factors and
Cautionary Statement Regarding Forward-Looking Statements in sanofi-aventis annual
report on Form 20-F for the year ended December 31, 2004. Other than as required by
applicable law, sanofi-aventis does not undertake any obligation to update or revise any
forward-looking information or statements.